Specifically, anti-CD79b monoclonal antibodies (mAbs), such as clone SN8, have demonstrated binding capabilities and efficient internalization into lymphoma cells, forming the rationale for developing ADCs as a treatment strategy for non-Hodgkin lymphomas [29,30]. Here, CD79B is linked to non-Hodgkin lymphoma.